Rowczenio Dorota, Stensland Maria, de Souza Gustavo A, Strøm Erik H, Gilbertson Janet A, Taylor Graham, Rendell Nigel, Minogue Shane, Efebera Yvonne A, Lachmann Helen J, Wechalekar Ashutosh D, Hawkins Philip N, Heimdal Ketil R, Selvig Kristian, Lægreid Inger K, Demoulin Nathalie, Aydin Selda, Gillmore Julian D, Wien Tale N
National Amyloidosis Centre, Centre for Amyloidosis and Acute Phase Proteins, Division of Medicine, Royal Free Campus, UCL, London, UK.
Norwegian Work Group of Amyloidosis, Department of Pathology, Oslo University Hospital Rikshospitalet, Oslo, Norway.
Kidney Int Rep. 2016 Nov 19;2(3):461-469. doi: 10.1016/j.ekir.2016.11.005. eCollection 2017 May.
Fibrinogen A alpha chain amyloidosis is an autosomal dominant disease associated with mutations in the fibrinogen A alpha chain () gene, and it is the most common cause of hereditary renal amyloidosis in the UK. Patients typically present with kidney impairment and progress to end-stage renal disease over a median time of 4.6 years.
Six patients presented with proteinuria, hypertension, and/or lower limb edema and underwent detailed clinical and laboratory investigations.
A novel gene mutation was identified in each case: 2 frameshift mutations F521Sfs27 and G519Efs30 and 4 single base substitutions G555F, E526K, E524K, R554H. In 5 subjects, extensive amyloid deposits were found solely within the glomeruli, which stained specifically with antibodies to fibrinogen A alpha chain, and in one of these cases, we found coexistent fibrinogen A alpha chain amyloidosis and anti-glomerular basement membrane antibody disease. One patient was diagnosed with light-chain amyloidosis after a bone marrow examination revealed a small clonal plasma cell population, and laser microdissection of the amyloid deposits followed by liquid chromatography and tandem mass spectrometry identified kappa light chain as the fibril protein.
We report 6 novel mutations in the gene: 5 were associated with renal fibrinogen A alpha chain amyloidosis and 1 was found to be incidental to light-chain amyloid deposits discovered in a patient with a plasma cell dyscrasia. Clinical awareness and suspicion of hereditary amyloidosis corroborated by genetic analysis and adequate typing using combined immunohistochemistry and laser microdissection and mass spectrometry is valuable to avoid misdiagnosis, especially when a family history of amyloidosis is absent.
纤维蛋白原Aα链淀粉样变性是一种常染色体显性疾病,与纤维蛋白原Aα链()基因突变相关,是英国遗传性肾淀粉样变性的最常见病因。患者通常表现为肾功能损害,在中位时间4.6年后进展为终末期肾病。
6例患者表现为蛋白尿、高血压和/或下肢水肿,并接受了详细的临床和实验室检查。
在每个病例中均鉴定出一种新的基因突变:2种移码突变F521Sfs27和G519Efs30以及4种单碱基替换G555F、E526K、E524K、R554H。在5名受试者中,仅在肾小球内发现广泛的淀粉样沉积物,其用抗纤维蛋白原Aα链抗体特异性染色,在其中1例中,我们发现纤维蛋白原Aα链淀粉样变性与抗肾小球基底膜抗体疾病共存。1例患者在骨髓检查发现少量克隆性浆细胞群后被诊断为轻链淀粉样变性,对淀粉样沉积物进行激光显微切割,随后进行液相色谱和串联质谱分析,确定κ轻链为原纤维蛋白。
我们报告了基因中的6种新突变:5种与肾纤维蛋白原Aα链淀粉样变性相关,1种被发现与一名浆细胞发育异常患者中发现的轻链淀粉样沉积物偶然相关。临床意识以及对遗传性淀粉样变性的怀疑,通过基因分析以及使用联合免疫组织化学、激光显微切割和质谱进行充分分型来证实,对于避免误诊很有价值,尤其是在没有淀粉样变性家族史的情况下。